A carregar...
Publicação
Private equity investment committee proposal - medpace lbo returns
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.08 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Medpace is a CRO company focused on providing scientifically driven outsourced clinical development services to the
biotechnology, pharma and medical-device industries. Its strong
positioning in a niche market, the high projected industry growth,
its strong and stable FCFs, and experienced management team
make it an ideal target, which would be further improved by our
developed business plan that will enhance its operations, expand
internationally, and capitalize on M&A trends. The business plan
is expected to deliver high returns, translating into a money
multiple of 3.28x and an IRR of 26.84%, which are further analysed
in the individual part of this paper.
Descrição
Palavras-chave
Contract research organization (Cro) Research & development (R&D) Mergers & acquisitions (M&A) Biopharma Leverage buyout (Lbo) Money multiple (Mm) Internal rate of return (Irr) Private equity (Pe)